{"metadata": {"source": "erowid", "title": "Erowid Methamphetamines Vault : FAQ", "description": "Answers to frequently asked questions about Methamphetamine.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/meth/meth_faq.shtml", "drug": "Methamphetamine", "cid": 10836, "substance": "meth", "category": "CHEMICALS", "erowid_column": "FAQ", "char_count": 49478, "word_count": 8104, "doc_id": "doc_193", "num_chunks": 69, "chunk_id": "193::chunk_48", "document_index": 193, "latency_s": 1.0891363999980967, "prompt_toks": 12018, "completion_toks": 66, "relevance_score": 1.357433e-07}, "content": "Drug: Methamphetamine | cid: 10836\nSource: erowid | Source description: Answers to frequently asked questions about Methamphetamine.\nErowid name: meth\nCategory: CHEMICALS\nField: FAQ\n\n                    Text: \n                    Sometimes 'speed' is present as waxy rocks that almost seem wet, but do not dry out properly. I am not sure what the cause of this is, but its most likely some form of oil, either formed in the reaction or left over from a very poor solvent. It may or may not be harmless depending upon what it is.\n\n\n                    Context: \n                    This excerpt discusses common physical characteristics of street methamphetamine, specifically the appearance of waxy, wet-looking rocks that resist drying, likely due to residual oils or poor solvent use. It is relevant to the section on street drug properties, coloration, and purity, providing insights into quality indicators and potential impurities in illicit meth products.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Oxymorphone (Opana) Vault : Legal Status", "description": "Information on the legal status of Oxymorphone (Opana).", "language": "No language found.", "url": "https://www.erowid.org/pharms/oxymorphone/oxymorphone_law.shtml", "drug": "Oxymorphone", "cid": 5284604, "substance": "oxymorphone", "category": "PHARMS", "erowid_column": "Law", "char_count": 4382, "word_count": 612, "doc_id": "doc_212", "num_chunks": 6, "chunk_id": "212::chunk_0", "document_index": 212, "latency_s": 0.8156742999999551, "prompt_toks": 1604, "completion_toks": 73, "relevance_score": 1.336388e-07}, "content": "Drug: Oxymorphone | cid: 5284604\nSource: erowid | Source description: Information on the legal status of Oxymorphone (Opana).\nErowid name: oxymorphone\nCategory: PHARMS\nField: Law\n\n                    Text: \n                    Plants & Drugs Index\n\nPlants\n\n\n\nChemicals\n\n\n\nPharmaceuticals\n\n\n\nHerbs\n\n\n\nSmarts\n\n\n\nAnimals\n\n\n\nBasics\n\n\n\nImages\n\n\n\nExperiences\n\n\n\nLaw\n\n\n\nChemistry\n\n\n\nDrug Testing\n\n\n\nHealth\n\n\n\nSpirit & Culture\n\n\n\nCommunity\n\n\n\nPlants Vault\n\nAmanitas\n\nCacti\n\nCannabis\n\nCoca\n\nPsilocybin Mushrooms\n\nSalvia divinorum\n\nTobacco\n\nMore . . .\n\nChemicals Vault\n\nAmphetamine\n\nDXM\n\nGHB\n\nKetamine\n\nLSD\n\nMDMA\n\nNitrous\n\nMore . . .\n\nPharmaceuticals Vault\n\nAlprazolam (Xanax)\n\nBupropion (Wellbutrin)\n\nDiazepam (Valium)\n\nFluoxetine (Prozac)\n\nHydrocodone (Vicodin)\n\nMethylphenidate (Ritalin)\n\nParoxetine (Paxil)\n\nMore . . .\n\nHerbs Vault\n\nCalamus\n\nDamiana\n\nFoxglove\n\nGinseng\n\nMilk Thistle\n\nPennyroyal\n\nValerian\n\nMore . . .\n\nNootropics Vault\n\nAdrafinil\n\nDMAE\n\nGinkgo biloba\n\nHydergine\n\nMelatonin\n\nPiracetam\n\nTryptophan\n\nMore . . .\n\nAnimals Vault\n\nBufo Toads\n\nPhyllomedusa bicolor\n\nMore . . .\n\nBasics Vaults\n\nDosage\n\nEffects\n\nFAQs\n\nHistory\n\nSlang\n\nImage Vaults\n\nPlants\n\nChemicals\n\nPharmaceuticals\n\nHerbs\n\nSmarts\n\nSubmit Image\n\n\n                    Context: \n                    This chunk is a section of the Plants & Drugs Index on the webpage, providing an organized overview of various substance vaults including plants, chemicals, pharmaceuticals, herbs, nootropics, animals, and basics such as dosage and effects. It is relevant for users seeking categorized information on psychoactive substances, their sources, and related topics within the comprehensive resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Naltrexone | C20H23NO4 | CID 5360515 - PubChem", "description": "Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5360515", "drug": "Naltrexone", "cid": 5360515, "char_count": 126230, "word_count": 16119, "doc_id": "doc_41", "num_chunks": 179, "chunk_id": "41::chunk_99", "document_index": 41, "latency_s": 1.2226388000126462, "prompt_toks": 33665, "completion_toks": 82, "relevance_score": 1.3259883e-07}, "content": "Drug: Naltrexone | cid: 5360515\nSource: pubchem | Source description: Naltrexone | C20H23NO4 | CID 5360515 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if applicable state law permits, and SAMHSA encourages them to do so. Prescribers registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed from registrants.\n\nThere are no longer limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required.\n\n\n                    Context: \n                    This excerpt details recent regulatory changes introduced by the MAT Act as of December 2022, eliminating the DATA-Waiver program and expanding prescribing authority for buprenorphine to all DEA-registered Schedule III practitioners. It emphasizes the removal of patient treatment limits and tracking requirements, highlighting updates relevant to medication regulation and prescribing practices discussed within the comprehensive chemotherapeutic and pharmacological information on naltrexone.\n                "}
